Fig. 5From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in GermanyEffect of erenumab on migraine-specific headache parameters after 3 months of treatment – medical chart review (N = 542); EM=episodic migraine (N = 271); CM = chronic migraine (N = 271)Back to article page